search
Back to results

Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes (MIRE)

Primary Purpose

Cystic Fibrosis-related Diabetes

Status
Recruiting
Phase
Phase 4
Locations
France
Study Type
Interventional
Intervention
A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP)
F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid)
Sponsored by
University Hospital, Strasbourg, France
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cystic Fibrosis-related Diabetes

Eligibility Criteria

10 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient with cystic fibrosis related diabetes aged over 18 years (no upper age limite)
  • Patient treated by multiple insulin injections (minimal three insulin injections per day or basal bolus insulin regimen) or insulin pump
  • Patient with CGM from over 3 months (at the signature of the study's informed consent) or patient not wearing a CGM device, but agreeing a CGM at the inclusion and at the end of each treatment period of 3 months
  • Naive patient of Fiasp or patient under Fiasp, having carried out a run-in period of one month with rapid acting insulin treatment
  • Affiliated to a social security scheme
  • Subject able to understand the objectives and the risks related to the research and to give a dated and signed informed consent
  • Subject having been informed of the results of the prior medical examination
  • Written informed consent, dated and signed before initiating any trial-related procedure

Exclusion Criteria:

  • Patient with type 1 or type 2 diabetes
  • Patient with cystic fibrosis related diabetes treated with 2 injections / day
  • Patient with an HbA1C greater than 12% who demonstrate therapeutic non-compliance
  • Patient pregnant (positive urinary pregnancy test) or wishing to pregnancy
  • Contraindication to Aspart insulin
  • Patient on lung transplant waiting list or transplanted within one year prior to the inclusion visit
  • Patient who started treatment with Trikafta® within 3 months prior to the inclusion visit
  • Patient who cannot be followed during 12 months
  • Subject in exclusion period (determined by previous or current clinical study)
  • Impossibility of giving the subject enlightened information (subject in emergency situation, difficulties of understanding, cognitive impairment...)
  • Subject under the protection of justice
  • Subject under guardianship or curatorship

Sites / Locations

  • Hôpitaux Universitaires de StrasbourgRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Group 1: A-F-A-F

Groupe 2: F-A-F-A

Arm Description

The study is an open, randomized, two-treatment - 4 periods of 3 months - 2 group cross-over superiority study. All patients will test both insulin treatments (A and F) in alternating periods. The patients of group 1 will start with pre-prandial aspart insulin (NovoRapid). Each treatment period will last 3 months.

The study is an open, randomized, two-treatment - 4 periods of 3 months - 2 group cross-over superiority study. All patients will test both insulin treatments (A and F) in alternating periods. The patients of group 2 will start with post prandial Faster-acting aspart insulin (FIASP).

Outcomes

Primary Outcome Measures

Change of time in range of blood glucose variation (70-180 mg/dl) versus baseline at the end of each treatment period of 3 months (the last 2 weeks of the period of 3 months) is assessed.

Secondary Outcome Measures

Other CGM parameters: mean glucose value per day (mg/dl)
Other CGM parameters: glucose area under the curve for glucose value>180mg/dl - number of glucose values<70 mg/dl-number of glucose values<53mg/dl
Other CGM parameters: time in range of blood glucose >180, >140 <70mg/dl
Hypoglycaemic events experienced by the patient - number of symptomatic hypoglycaemic events under 70 mg/dl par mois - number of major hypoglycaemic events per year - number of nocturnal hypoglycaemic events per month
Markers of nutritional status: Body Mass Index (BMI)
Markers of nutritional status : bioelectrical impedance - Albumin and Pre albumin
Markers of nutritional status : Albumin and Pre albumin (g/l)
Markers of metabolic status: HbA1c (mmol/l and %)
Markers of metabolic status: daily exogenous need of insulin (UI/day)
Assessment of respiratory function parameters : FEV1, CV (L and %)
Assessment of respiratory function parameters : O2 saturation (%)
Assessment of respiratory function parameters : Number of cures of IV antibiotics per year (collect this information at each visit)
Number patients with severe hypoglycaemia and serious adverse events
Other CGM parameters: Time in range of blood glucose 70-140 mg/dl

Full Information

First Posted
April 30, 2020
Last Updated
January 5, 2023
Sponsor
University Hospital, Strasbourg, France
search

1. Study Identification

Unique Protocol Identification Number
NCT04381429
Brief Title
Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes
Acronym
MIRE
Official Title
Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes : MIRE Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 17, 2020 (Actual)
Primary Completion Date
August 2025 (Anticipated)
Study Completion Date
August 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Strasbourg, France

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Cystic fibrosis related diabetes (CFRD) is a major factor of morbidity and mortality at all disease stages. Insulin deficiency has serious clinical consequences by increasing malnutrition, since protein and lipid catabolism is accelerated in chronic infections. Traditionally, insulin is injected before a meal. Yet, in these patients with highly varied and often staggered nutritional intakes, insulin injection can result in an increased risk of postprandial hypoglycaemia, all the more so as CF patients exhibit decreased glucagon secretion. Recent progress in the development of new insulins mimicking the physiological secretion more closely has led to ultra-fast insulins (fast aspart), allowing for postprandial hyperglycaemia to be better controlled. In Type 1 diabetics treated with basal-bolus, faster-acting aspart insulin injected after a meal enabled metabolic control comparable to injection of aspart insulin prior to the meal. Fast apart insulin is of particular interest with regard to CFRD, wherein postprandial hyperglycaemia occurs early. In CFRD, these insulins are likewise advantageous in that they can be injected after the meal, thus permitting more flexibility in patients with highly varied diets. Moreover, the insulin dose can be adapted depending on dietary intake, thus preventing hypoglycaemia secondary to highly-varied carbohydrate intakes. Due to its flexibility, this insulin therapy is likely to be better accepted by patients with cystic fibrosis.
Detailed Description
The investigators hypothesis that post prandial administration of Insulin faster-acting aspart insulin in patients with CFRD may contribute to a better metabolic control with a decrease of hypoglycaemia and facilitate insulin administration according to the real food intake. The use of Insulin faster-acting aspart insulin will facilitate the functional insulin therapy. More particularly for CF patients, optimization of metabolic control should contribute to maintain a good nutritional status and to slowing the decline of respiratory function and improve the quality of life. Patients with cystic fibrosis related diabetes and treated by multiple insulin injection (minimal three insulin injection per day or basal bolus insulin regimen) or insulin pump with CGM from over 3 months were included in an open, randomized, two-treatments - 4 periods of 3 months - 2 groups cross-over superiority study. Each group of patients will test both insulin treatments (A = pre prandial Aspart insulin, F = post prandial Faster-acting aspart insulin) in alternating periods with the following sequences: Group 1: A-F-A-F, Group 2: F-A-F-A The patients will be randomized to either one or the other sequence, which defines the groups, and take A or F in each of the 4 periods of the study. Each treatment period will last 3 months. CGM (free style libre, Abott) will be performed for 2 weeks at baseline and after each 4 months period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystic Fibrosis-related Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group 1: A-F-A-F
Arm Type
Active Comparator
Arm Description
The study is an open, randomized, two-treatment - 4 periods of 3 months - 2 group cross-over superiority study. All patients will test both insulin treatments (A and F) in alternating periods. The patients of group 1 will start with pre-prandial aspart insulin (NovoRapid). Each treatment period will last 3 months.
Arm Title
Groupe 2: F-A-F-A
Arm Type
Active Comparator
Arm Description
The study is an open, randomized, two-treatment - 4 periods of 3 months - 2 group cross-over superiority study. All patients will test both insulin treatments (A and F) in alternating periods. The patients of group 2 will start with post prandial Faster-acting aspart insulin (FIASP).
Intervention Type
Drug
Intervention Name(s)
A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP)
Other Intervention Name(s)
All patients will have both treatments: NovoRapid + FIASP
Intervention Description
A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
Intervention Type
Drug
Intervention Name(s)
F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid)
Other Intervention Name(s)
All patients will have both treatments: NovoRapid + FIASP
Intervention Description
A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
Primary Outcome Measure Information:
Title
Change of time in range of blood glucose variation (70-180 mg/dl) versus baseline at the end of each treatment period of 3 months (the last 2 weeks of the period of 3 months) is assessed.
Time Frame
This measurement is assessed at the end of each treatment period of 3 months (the last 2 weeks of the period of 3 months). Month 3, month 6, month 9 and month 12.
Secondary Outcome Measure Information:
Title
Other CGM parameters: mean glucose value per day (mg/dl)
Time Frame
screening(Day 0 to 3 months to Day 0)-Inclusion visit (Day 0)-visit Month 3(3 months after inclusion)-Month 6-Month 9-Month 12
Title
Other CGM parameters: glucose area under the curve for glucose value>180mg/dl - number of glucose values<70 mg/dl-number of glucose values<53mg/dl
Time Frame
screening(Day 0 to 3 months to Day 0)-Inclusion visit (Day 0)-visit Month 3(3 months after inclusion)-Month 6-Month 9-Month 12
Title
Other CGM parameters: time in range of blood glucose >180, >140 <70mg/dl
Time Frame
screening(Day 0 to 3 months to Day 0)-Inclusion visit (Day 0)-visit Month 3(3 months after inclusion)-Month 6-Month 9-Month 12
Title
Hypoglycaemic events experienced by the patient - number of symptomatic hypoglycaemic events under 70 mg/dl par mois - number of major hypoglycaemic events per year - number of nocturnal hypoglycaemic events per month
Time Frame
Inclusion visit (Day0)-visit Month 3(3 months after inclusion visit)-Visit Month 6-Month 9-Month 12
Title
Markers of nutritional status: Body Mass Index (BMI)
Time Frame
visit (Day 0 to 3 months to Day 0-Inclusion visit (Day 0)-visit Month 3 (3 months after inclusion visit)-Visit Month 6-Month 9-Month 12
Title
Markers of nutritional status : bioelectrical impedance - Albumin and Pre albumin
Time Frame
visit (Day 0 to 3 months to Day 0-Inclusion visit (Day 0)-visit Month 3 (3 months after inclusion visit)-Visit Month 6-Month 9-Month 12
Title
Markers of nutritional status : Albumin and Pre albumin (g/l)
Time Frame
visit (Day 0 to 3 months to Day 0-Inclusion visit (Day 0)-visit Month 3 (3 months after inclusion visit)-Visit Month 6-Month 9-Month 12
Title
Markers of metabolic status: HbA1c (mmol/l and %)
Time Frame
screening visit (Day 0 to 3 months to Day 0)-Inclusion visit (Day 0)-visit Month 3 (3 months after inclusion visit)-Visit Month 6-Month 9-Month 12
Title
Markers of metabolic status: daily exogenous need of insulin (UI/day)
Time Frame
screening visit (Day 0 to 3 months to Day 0)-Inclusion visit (Day 0)-visit Month 3 (3 months after inclusion visit)-Visit Month 6-Month 9-Month 12
Title
Assessment of respiratory function parameters : FEV1, CV (L and %)
Time Frame
screening visit (Day 0 to 3 months to Day 0)-Inclusion visit (Day 0)-visit Month 3 (3 months after inclusion visit)-Visit Month 6-Month 9-Month 12
Title
Assessment of respiratory function parameters : O2 saturation (%)
Time Frame
screening visit (Day 0 to 3 months to Day 0)-Inclusion visit (Day 0)-visit Month 3 (3 months after inclusion visit)-Visit Month 6-Month 9-Month 12
Title
Assessment of respiratory function parameters : Number of cures of IV antibiotics per year (collect this information at each visit)
Time Frame
screening visit (Day 0 to 3 months to Day 0)-Inclusion visit (Day 0)-visit Month 3 (3 months after inclusion visit)-Visit Month 6-Month 9-Month 12
Title
Number patients with severe hypoglycaemia and serious adverse events
Time Frame
Inclusion visit (Day 0)-visit Month 3(3 months after inclusion visit)-Visit Month 6-Month 9-Month 12
Title
Other CGM parameters: Time in range of blood glucose 70-140 mg/dl
Time Frame
screening visit (Day 0 to 3 months to Day 0)-Inclusion visit (Day 0)-visit Month 3 (3 months after inclusion visit)-Visit Month 6-Month 9-Month 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient with cystic fibrosis related diabetes aged over 10 years (no upper age limite) Patient treated by multiple insulin injections (minimal three insulin injections per day or basal bolus insulin regimen) or insulin pump Patient with CGM from over 3 months (at the signature of the study's informed consent) or patient not wearing a CGM device, but agreeing a CGM at the inclusion and at the end of each treatment period of 3 months Naive patient of Fiasp or patient under Fiasp, having carried out a run-in period of one month with rapid acting insulin treatment Affiliated to a social security scheme Subject able to understand the objectives and the risks related to the research and to give a dated and signed informed consent Subject having been informed of the results of the prior medical examination Written informed consent, dated and signed before initiating any trial-related procedure (if the subject is a minor, the consent must be signed by the 2 legal representative and the patient if he/she is able to give consent) Exclusion Criteria: Patient with type 1 or type 2 diabetes Patient with cystic fibrosis related diabetes treated with 2 injections / day Patient with an HbA1C greater than 12% who demonstrate therapeutic non-compliance Patient pregnant (positive urinary pregnancy test) or wishing to pregnancy Contraindication to Aspart insulin Patient on lung transplant waiting list or transplanted within one year prior to the inclusion visit Patient who started treatment with Trikafta® within 3 months prior to the inclusion visit Patient who cannot be followed during 12 months Subject in exclusion period (determined by previous or current clinical study) Impossibility of giving the subject enlightened information (subject in emergency situation, difficulties of understanding, cognitive impairment...) Subject under the protection of justice Subject under guardianship or curatorship
Facility Information:
Facility Name
Hôpitaux Universitaires de Strasbourg
City
Strasbourg
ZIP/Postal Code
67091
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laurence KESSLER, MD PhD
Phone
0388116267
Ext
+33
Email
laurence.kessler@chru-strasbourg.fr

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes

We'll reach out to this number within 24 hrs